Affomix, City of Hope Collaborate to Create Proteomic Profiles of Cancer | GenomeWeb

This story originally ran on Jan. 19.

Antibody firm Affomix will supply the City of Hope with monoclonal antibodies that will be used to create proteomic profiles that are characteristic of certain cancers, the company announced today.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.